Leadless and Conduction System Pacing are the future of pacing, transforming the patient experience with safe and effective therapeutic options.
The convergence of leadless and conduction system pacing is the desired future solution; in the interim there is a role for each therapy on the patient continuum of care.
Micra™ is a minimally invasive approach to pacing that reduces complications, redefines the patient experience, and preserves vasculature for future treatment options. It is also the only leadless single device solution for patients with AV block.
SelectSecure™ 3830 is the first and only lead approved for HBP and LBBAP.
Together, we can provide patients with the right therapy.
Now and in the future.
References
1
Nippoldt D, Whiting J. Micra transcatheter pacing system device volume characterization comparison. November 2014. Medtronic data on file.
2
Ellenbogen KA, Left bundle branch area pacing using the Model 3830 lead: A systematic literature review and meta-analysis, Presented at APHRS 2022. 19 November 2022. Singapore.
3
Kron J, Performance of Model 3830 Left Bundle Branch Area Pacing: Results from CareLink and Registration Data, Presented at APHRS 2022. 18 November 2022. Singapore
4
Vijayaraman P, Model 3830 Lead Performance for Left Bundle Branch Area Pacing: Results from a Multi-Center Registry, Presented at APHRS 2022. 19 November 2022. Singapore